146 related articles for article (PubMed ID: 37530954)
21. Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients.
Coleman CI; Vaitsiakhovich T; Nguyen E; Weeda ER; Sood NA; Bunz TJ; Schaefer B; Meinecke AK; Eriksson D
Clin Cardiol; 2018 Jan; 41(1):119-125. PubMed ID: 29360144
[TBL] [Abstract][Full Text] [Related]
22. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
[TBL] [Abstract][Full Text] [Related]
25. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
[TBL] [Abstract][Full Text] [Related]
26. Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation.
Steinberg BA; Ballew NG; Greiner MA; Lippmann SJ; Curtis LH; O'Brien EC; Patel MR; Piccini JP
JACC Clin Electrophysiol; 2019 Dec; 5(12):1384-1392. PubMed ID: 31857036
[TBL] [Abstract][Full Text] [Related]
27. Stroke prevention of thoracoscopic left atrial appendage clipping in patients with non-valvular atrial fibrillation at high risk of stroke and bleeding: study protocol for a non-randomised controlled clinical trial.
Ye C; Han X; Chen Y; Liu F; Ma H; Yang Y; Liu Y; Hu Q; Yao Q; Xie W; Xu D
BMJ Open; 2022 Oct; 12(10):e063931. PubMed ID: 36307161
[TBL] [Abstract][Full Text] [Related]
28. Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain.
Polo García J; Vargas Ortega D; Formiga F; Unzueta I; Fernández de Cabo S; Chaves J
Semergen; 2019 Sep; 45(6):396-405. PubMed ID: 30573367
[TBL] [Abstract][Full Text] [Related]
29. Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016.
Ardeshirrouhanifard S; An H; Goyal RK; Raji MA; Segal JB; Alexander GC; Mehta HB
Pharmacotherapy; 2022 May; 42(5):375-386. PubMed ID: 35364622
[TBL] [Abstract][Full Text] [Related]
30. Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database.
Truong B; Hornsby L; Fox B; Chou C; Zheng J; Qian J
J Thromb Thrombolysis; 2024 Apr; 57(4):638-649. PubMed ID: 38504063
[TBL] [Abstract][Full Text] [Related]
31. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs.
Deitelzweig S; Sah J; Kang A; Russ C; Preib M; Dhamane AD; Ratiu A; Cato M; Alfred T; Levi E; Di Fusco M
Am J Cardiol; 2022 Jan; 163():43-49. PubMed ID: 34930532
[TBL] [Abstract][Full Text] [Related]
33. Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial.
Pokorney SD; Cocoros N; Al-Khalidi HR; Haynes K; Li S; Al-Khatib SM; Corrigan-Curay J; Driscoll MR; Garcia C; Calvert SB; Harkins T; Jin R; Knecht D; Levenson M; Lin ND; Martin D; McCall D; McMahill-Walraven C; Nair V; Parlett L; Petrone A; Temple R; Zhang R; Zhou Y; Platt R; Granger CB
JAMA Netw Open; 2022 May; 5(5):e2214321. PubMed ID: 35639381
[TBL] [Abstract][Full Text] [Related]
34. Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database.
Munir MB; Hlavacek P; Keshishian A; Guo JD; Mallampati R; Ferri M; Russ C; Emir B; Cato M; Yuce H; Hsu JC
J Interv Card Electrophysiol; 2023 Apr; 66(3):771-782. PubMed ID: 35804258
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Lip GYH; Keshishian A; Kang A; Luo X; Atreja N; Zhang Y; Schuler P; Jiang J; Yuce H; Deitelzweig S
J Thromb Thrombolysis; 2022 Jul; 54(1):33-46. PubMed ID: 35579733
[TBL] [Abstract][Full Text] [Related]
36. Role of cardiovascular implantable electronic devices in delivering individualized disease-guided management of patients with non-valvular atrial fibrillation and high bleeding risk.
Mascarenhas DAN; Sharma M; Ziegler PD; Kantharia BK
Acta Cardiol; 2019 Apr; 74(2):131-139. PubMed ID: 29863432
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
[TBL] [Abstract][Full Text] [Related]
38. Patients With Atrial Fibrillation Who Are Not on Anticoagulant Treatment Due to Increased Bleeding Risk Are Common and Have a High Risk of Stroke.
Redfors B; Gray WA; Lee RJ; Ellenbogen KA; Bonafede M; Ben-Yehuda O
JACC Clin Electrophysiol; 2017 Dec; 3(12):1369-1376. PubMed ID: 29759666
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
40. A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.
Brown JD; Shewale AR; Dherange P; Talbert JC
Drugs Aging; 2016 Jun; 33(6):427-36. PubMed ID: 27154397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
